# US 2005/0090658 A1 · Gene related to migraine in man

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0090658 A1
- Document ID: US20050090658A1
- Status: Published application
- Kind: A1
- Application number: 10/619,898
- Filed: 2003-07-14
- Published: 2005-04-28
- Earliest claimed: 1996-09-27
- Assignees: Rijksuniversiteit te Leiden
- Inventors: Rune Frants; Michel Ferrari; Gisela Terwindt; Roel Ophoff
- Web page: https://patentgrep.com/patent/US20050090658A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

Genes for familial hemeplegic migraine (FHM), episodic ataxia type-2 (EA-2), common forms of migraine, and other episodic neurological disorders, such as epilepsy, have been mapped to chromosome 19p13. A brain-specific P/Q type calcium channel subunit gene, covering 300 kb with 47 exons is provided. The exons and their surroundings reveal polymorphic variations and deleterious mutations that are linked to various types of cation channel dysfunctions causing episodic neurological disorders in man or animals.

## Claims

### Claim 1

An isolated nucleic acid encoding an α1 subunit of a P/O-type gated calcium channel or a specific fragment or homolog or derivative of said calcium channel.

### Claim 2 (depends on 1)

The nucleic acid according to claim 1, wherein said nucleic acid is a cDNA.

### Claim 3 (depends on 2)

The cDNA according to claim 2, wherein said cDNA comprises a 6789 bp coding region.

### Claim 4 (depends on 1)

The nucleic acid according to claim 1, wherein said cDNA is of human origin.

### Claim 5 (depends on 4)

The nucleic acid according to claim 4, wherein the nucleotide sequence of said nucleic acid has at least 70% homology with the nucleotide sequence depicted in SEQ ID NO: 1-42.

### Claim 6 (depends on 1)

The nucleic acid according to claim 1, wherein the nucleotide sequence of said nucleic acid has at least 90% homology with the nucleotide sequence depicted in SEQ ID NO: 1-42.

### Claim 7 (depends on 38)

The nucleic acid according to claim 38, wherein said one or more mutation is at a codon in said nucleic acid which results in an amino acid change in said calcium channel respectively selected from the group consisting of codon 192: replacement of arginine by glutamine: codon 666: a replacement of threonine by methionine: codon 714, a replacement of valine by alanine; and codon 1811: a replacement of isoleucine by leucine.

### Claim 8 (depends on 1)

An isolated nucleic acid according to claim 1, wherein said nucleic acid comprises a mutation at codon 666 resulting in the replacement of threonine by methionine.

### Claim 9 (depends on 1)

An isolated nucleic acid according to claim 1, wherein said nucleic acid comprises a mutation at codon 714 resulting in the replacement of valine by alanine.

### Claim 10 (depends on 1)

An isolated nucleic acid according to claim 1, wherein said nucleic acid comprises a mutation at codon 1811 resulting in the replacement of isoleucine by leucine.

### Claim 11 (depends on 1)

The isolated nucleic acid according to claim 1, wherein said nucleic acid comprises a CA-repeat sequence.

### Claim 12 (depends on 1)

The isolated nucleic acid according to claim 1, wherein said nucleic acid comprises a (CAG)n repeat sequence as shown in table 2.

### Claim 13 (depends on 1)

The isolated nucleic acid according to claim 1, wherein the coding sequence of said nucleic acid comprises a polymorphism.

### Claim 14 (depends on 13)

The isolated nucleic acid according to claim 13, wherein said polymorphism comprises a nucleotide change shown in table 2.

### Claim 15 (depends on 13, 14)

The isolated nucleic acid according to claim 13 or 14, wherein said nucleic acid comprises a mutation at codon 454 resulting in a replacement of alanine by threonine in said calcium channel.

### Claim 16 (depends on 1)

The isolated nucleic acid according to claim 1, wherein said nucleic acid comprises a deletion.

### Claim 17 (depends on 1)

The isolated nucleic acid according to claim 1, wherein said nucleic acid comprises a frameshift at codon 1266.

### Claim 18 (depends on 1)

The isolated nucleic acid according to claim 1, wherein said nucleic acid comprises a mutation which results in aberrant splicing.

### Claim 19 (depends on 18)

The isolated nucleic acid according to claim 18, wherein said aberrant splicing is of intron 28.

### Claim 20

An isolated nucleic acid encoding a calcium channel subunit or a functional fragment thereof, wherein said nucleic acid is obtained from a mammal diagnosed as having one or both of familial hemiplegic migraine and episodic ataxia type 2.

### Claim 21 (depends on 20)

The isolated nucleic acid according to claim 20, wherein said calcium channel subunit is a β2 subunit, wherein said nucleic acid is derived from, related to or associated with a gene which in humans is present on chromosome 10p12.

### Claim 22 (depends on 1, 20)

A method for identifying a gene which encodes a P/O-type gated calcium channel, said method comprising:
contacting genetic material with a a nucleic acid molecule or a fragment of fragments thereof according to claim 1 or claim 20.

### Claim 23 (depends on 22)

The method according to claim 22 wherein said gene is related to an episodic neurological disorder.

### Claim 24 (depends on 22)

The method according to claim 22 wherein said gene is related to migraine.

### Claim 25 (depends on 22)

The method according to claim 22, wherein said gene is related to one or more neurological disorder selected from the group consisting of FHM, EA-2, and autosomal dominant cerebellar ataxia.

### Claim 26 (depends on 20)

A method of distinguishing between alleles of a gene which encodes a P/Q-type gated calcium channel, said method comprising:
contacting said gene with a nucleic acid molecule or a fragment of fragments thereof according to claim 20.

### Claim 27 (depends on 23, 26)

The method according to claim 23 or claim 26, wherein said gene is of human origin.

### Claim 28 (depends on 23, 26)

The method according to claim 23 or claim 26, wherein said gene is identified in a cell or an animal.

### Claim 29 (depends on 1)

A recombinant expression vector comprising a nucleic acid molecule according to claim 1.

### Claim 30 (depends on 29)

A cell or an animal comprising a vector according to claim 29.

### Claim 31 (depends on 1)

A transgenic non-human cell, an isolated transgenic cell or a non-human transgenic animal comprising a nucleic acid molecule according to claim 1.

### Claim 32 (depends on 28)

A non-human cell, an isolated cell or a non-human animal comprising a gene which encodes a P/Q-type gated calcium channel identified by the method according to claim 28.

### Claim 33 (depends on 1)

A non-human cell, an isolated cell or a non-human animal comprising a genome in which a nucleic acid corresponding to said nucleic acid according to claim 1 has been modified.

### Claim 34

A method for screening for an agent useful for treating FHM, EA-2, SCA6, migraine or other neurological disorder associated with cation channel dysfunction, said method comprising:
comparing phenotypic characteristics relating to cation channel dysfunction of a first animal contacted with said agent with those of a second animal not contacted with said agents wherein the genome of said first animal and said second animal comprise a nucleic acid encoding dysfunctional α1 subunit of a P/Q-type gated calcium channel, whereby an agent useful for treating FHM, EA-2, SCA6, migraine or other neurological disorder is identified by a decrease in phenotypic characteristics relating to calcium channel dysfunction in said first transgenic mouse in comparison to said second transgenic mouse.

### Claim 35 (depends on 1)

A protein or peptide comprising an amino acid sequence encoded by a nucleic acid molecule according to claim 1.

### Claim 36 (depends on 35)

A natural or synthetic antibody directed against a protein or peptide according to claim 35.

### Claim 37 (depends on 38)

A method for diagnosing FHM, EA-2, SCA6, migraine or other neurological disorders associated with cation channel dysfunction, said method comprising:
detecting a protein or a peptide encoded by the nucleic acid according to claim 38 in a patient.

### Claim 38 (depends on 1)

The nucleic acid according to claim 1, wherein said nucleic acid comprises one or more mutation which results in dysfunction of said calcium channel.

### Claim 39

A non-human animal with phenotypic characteristics relating to calcium channel dysfunction, the genome of which comprises:
a nucleic acid encoding dysfunctional α1 subunit of a P/Q-type gated calcium channel.

### Claim 40 (depends on 39)

The non-human animal according to claim 39, wherein said non-human animal is a mouse.
